STOCK TITAN

[Form 4] Worthington Steel, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) filed a Form 4 disclosing routine equity awards to director Elizabeth M. Anderson on 26 June 2025.

  • Restricted Stock Units (RSUs): Anderson received 3,142 shares of common stock at no cost, raising her direct beneficial ownership to 23,215 shares (inclusive of the new RSUs).
  • Stock Option Grant: She was granted an option on 11,574 shares with a $37.48 exercise price, expiring 26 June 2035. The option vests in full on the earlier of the first anniversary of the grant or immediately prior to the next annual meeting, provided she remains a service provider.
  • Indirect Holdings: Anderson also reports 26,990 shares held through the David W. Anderson 1996 Irrevocable Trust.
  • No Dispositions: The filing records no sales of RVMD shares.

The transactions represent standard director compensation and have an immaterial impact on the company’s overall share count or governance structure. No performance metrics, strategic developments, or other material events were disclosed in this filing.

Revolution Medicines, Inc. (RVMD) ha presentato un Modulo 4 che comunica l'assegnazione ordinaria di azioni alla direttrice Elizabeth M. Anderson il 26 giugno 2025.

  • Unità Azionarie Vincolate (RSU): Anderson ha ricevuto 3.142 azioni ordinarie a titolo gratuito, portando la sua proprietà diretta a 23.215 azioni (inclusi i nuovi RSU).
  • Assegnazione di Opzioni su Azioni: Le è stata concessa un'opzione su 11.574 azioni con un prezzo di esercizio di $37,48, valida fino al 26 giugno 2035. L'opzione matura completamente al primo anniversario della concessione o immediatamente prima della prossima assemblea annuale, a condizione che rimanga in servizio.
  • Partecipazioni Indirette: Anderson detiene inoltre 26.990 azioni attraverso il David W. Anderson 1996 Irrevocable Trust.
  • Nessuna Cessione: Nel documento non sono registrate vendite di azioni RVMD.

Le transazioni rappresentano una normale compensazione per i direttori e hanno un impatto trascurabile sul numero complessivo di azioni o sulla struttura di governance della società. Nel documento non sono stati divulgati parametri di performance, sviluppi strategici o altri eventi rilevanti.

Revolution Medicines, Inc. (RVMD) presentó un Formulario 4 revelando adjudicaciones rutinarias de acciones a la directora Elizabeth M. Anderson el 26 de junio de 2025.

  • Unidades de Acciones Restringidas (RSUs): Anderson recibió 3,142 acciones ordinarias sin costo, aumentando su propiedad directa a 23,215 acciones (incluyendo las nuevas RSUs).
  • Concesión de Opciones sobre Acciones: Se le otorgó una opción sobre 11,574 acciones con un precio de ejercicio de $37.48, que vence el 26 de junio de 2035. La opción se consolida totalmente en el primer aniversario de la concesión o justo antes de la próxima junta anual, siempre que continúe en servicio.
  • Participaciones Indirectas: Anderson también reporta 26,990 acciones mantenidas a través del David W. Anderson 1996 Irrevocable Trust.
  • No hay Disposiciones: El informe no registra ventas de acciones de RVMD.

Las transacciones representan una compensación estándar para directores y tienen un impacto insignificante en el recuento total de acciones o la estructura de gobierno de la compañía. No se divulgaron métricas de desempeño, desarrollos estratégicos u otros eventos materiales en esta presentación.

Revolution Medicines, Inc. (RVMD)는 2025년 6월 26일 이사 Elizabeth M. Anderson에게 정기 주식 보상을 공개하는 Form 4를 제출했습니다.

  • 제한 주식 단위(RSU): Anderson은 비용 없이 3,142주의 보통주를 받았으며, 이를 포함해 그녀의 직접 소유 주식은 총 23,215주가 되었습니다.
  • 주식 옵션 부여: 그녀는 11,574주에 대해 행사가격 $37.48인 옵션을 부여받았으며, 만료일은 2035년 6월 26일입니다. 이 옵션은 부여일로부터 1주년 또는 다음 연례 총회 직전에 전액 취득되며, 계속 근무 중인 경우에 한합니다.
  • 간접 보유: Anderson은 또한 David W. Anderson 1996 Irrevocable Trust를 통해 26,990주를 보유하고 있습니다.
  • 매도 없음: 제출 서류에는 RVMD 주식 매도 기록이 없습니다.

이번 거래는 표준 이사 보상에 해당하며 회사의 전체 주식 수나 지배구조에 미미한 영향을 미칩니다. 이번 제출에서는 성과 지표, 전략적 개발 또는 기타 중요한 사건은 공개되지 않았습니다.

Revolution Medicines, Inc. (RVMD) a déposé un formulaire 4 révélant des attributions d’actions ordinaires de routine à la directrice Elizabeth M. Anderson le 26 juin 2025.

  • Unités d’actions restreintes (RSU) : Anderson a reçu 3 142 actions ordinaires gratuitement, portant sa propriété directe à 23 215 actions (incluant les nouvelles RSU).
  • Attribution d’options d’achat d’actions : Elle a reçu une option sur 11 574 actions avec un prix d’exercice de 37,48 $, expirant le 26 juin 2035. L’option devient entièrement acquise au premier anniversaire de l’attribution ou juste avant la prochaine assemblée annuelle, à condition qu’elle reste prestataire de services.
  • Participations indirectes : Anderson détient également 26 990 actions via le David W. Anderson 1996 Irrevocable Trust.
  • Aucune cession : Le dépôt ne rapporte aucune vente d’actions RVMD.

Ces transactions représentent une rémunération standard pour les administrateurs et ont un impact négligeable sur le nombre total d’actions ou la structure de gouvernance de l’entreprise. Aucun indicateur de performance, développement stratégique ou autre événement important n’a été divulgué dans ce dépôt.

Revolution Medicines, Inc. (RVMD) reichte am 26. Juni 2025 ein Formular 4 ein, das routinemäßige Aktienzuteilungen an die Direktorin Elizabeth M. Anderson offenlegt.

  • Restricted Stock Units (RSUs): Anderson erhielt 3.142 Stammaktien kostenlos, wodurch ihr direkter Anteil auf 23.215 Aktien anstieg (einschließlich der neuen RSUs).
  • Aktienoptionszuteilung: Ihr wurde eine Option auf 11.574 Aktien mit einem Ausübungspreis von 37,48 $ gewährt, die am 26. Juni 2035 verfällt. Die Option wird vollständig am früheren Zeitpunkt des ersten Jahrestages der Gewährung oder unmittelbar vor der nächsten Hauptversammlung fällig, vorausgesetzt, sie bleibt weiterhin Dienstleisterin.
  • Indirekte Beteiligungen: Anderson meldet außerdem 26.990 Aktien, die über den David W. Anderson 1996 Irrevocable Trust gehalten werden.
  • Keine Veräußerungen: Die Einreichung verzeichnet keine Verkäufe von RVMD-Aktien.

Die Transaktionen stellen eine übliche Vergütung für Direktoren dar und haben einen unerheblichen Einfluss auf die Gesamtzahl der Aktien oder die Governance-Struktur des Unternehmens. Es wurden keine Leistungskennzahlen, strategischen Entwicklungen oder sonstige wesentliche Ereignisse in dieser Einreichung offengelegt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director equity awards; negligible dilution; neutral for valuation.

This Form 4 shows a typical annual equity package: 3,142 RSUs plus an 11,574-share option at $37.48. No shares were sold, so there is no bearish signal. The aggregate 14.7 k shares represent less than 0.02 % of RVMD’s ~86 m basic shares, implying de minimis dilution. Because awards vest within a year, the option aligns director incentives with shareholder value but does not materially alter ownership structure.

TL;DR: Standard compensation; reinforces director alignment; governance status unchanged.

The grant follows normal independent-director compensation practices under RVMD’s 2020 Plan. A single-cliff vest aligns tenure with shareholder interests. Indirect trust holdings remain static, suggesting no hidden accumulation or disposal. The filing is compliant with Section 16(a) timing requirements and does not indicate any governance concerns.

Revolution Medicines, Inc. (RVMD) ha presentato un Modulo 4 che comunica l'assegnazione ordinaria di azioni alla direttrice Elizabeth M. Anderson il 26 giugno 2025.

  • Unità Azionarie Vincolate (RSU): Anderson ha ricevuto 3.142 azioni ordinarie a titolo gratuito, portando la sua proprietà diretta a 23.215 azioni (inclusi i nuovi RSU).
  • Assegnazione di Opzioni su Azioni: Le è stata concessa un'opzione su 11.574 azioni con un prezzo di esercizio di $37,48, valida fino al 26 giugno 2035. L'opzione matura completamente al primo anniversario della concessione o immediatamente prima della prossima assemblea annuale, a condizione che rimanga in servizio.
  • Partecipazioni Indirette: Anderson detiene inoltre 26.990 azioni attraverso il David W. Anderson 1996 Irrevocable Trust.
  • Nessuna Cessione: Nel documento non sono registrate vendite di azioni RVMD.

Le transazioni rappresentano una normale compensazione per i direttori e hanno un impatto trascurabile sul numero complessivo di azioni o sulla struttura di governance della società. Nel documento non sono stati divulgati parametri di performance, sviluppi strategici o altri eventi rilevanti.

Revolution Medicines, Inc. (RVMD) presentó un Formulario 4 revelando adjudicaciones rutinarias de acciones a la directora Elizabeth M. Anderson el 26 de junio de 2025.

  • Unidades de Acciones Restringidas (RSUs): Anderson recibió 3,142 acciones ordinarias sin costo, aumentando su propiedad directa a 23,215 acciones (incluyendo las nuevas RSUs).
  • Concesión de Opciones sobre Acciones: Se le otorgó una opción sobre 11,574 acciones con un precio de ejercicio de $37.48, que vence el 26 de junio de 2035. La opción se consolida totalmente en el primer aniversario de la concesión o justo antes de la próxima junta anual, siempre que continúe en servicio.
  • Participaciones Indirectas: Anderson también reporta 26,990 acciones mantenidas a través del David W. Anderson 1996 Irrevocable Trust.
  • No hay Disposiciones: El informe no registra ventas de acciones de RVMD.

Las transacciones representan una compensación estándar para directores y tienen un impacto insignificante en el recuento total de acciones o la estructura de gobierno de la compañía. No se divulgaron métricas de desempeño, desarrollos estratégicos u otros eventos materiales en esta presentación.

Revolution Medicines, Inc. (RVMD)는 2025년 6월 26일 이사 Elizabeth M. Anderson에게 정기 주식 보상을 공개하는 Form 4를 제출했습니다.

  • 제한 주식 단위(RSU): Anderson은 비용 없이 3,142주의 보통주를 받았으며, 이를 포함해 그녀의 직접 소유 주식은 총 23,215주가 되었습니다.
  • 주식 옵션 부여: 그녀는 11,574주에 대해 행사가격 $37.48인 옵션을 부여받았으며, 만료일은 2035년 6월 26일입니다. 이 옵션은 부여일로부터 1주년 또는 다음 연례 총회 직전에 전액 취득되며, 계속 근무 중인 경우에 한합니다.
  • 간접 보유: Anderson은 또한 David W. Anderson 1996 Irrevocable Trust를 통해 26,990주를 보유하고 있습니다.
  • 매도 없음: 제출 서류에는 RVMD 주식 매도 기록이 없습니다.

이번 거래는 표준 이사 보상에 해당하며 회사의 전체 주식 수나 지배구조에 미미한 영향을 미칩니다. 이번 제출에서는 성과 지표, 전략적 개발 또는 기타 중요한 사건은 공개되지 않았습니다.

Revolution Medicines, Inc. (RVMD) a déposé un formulaire 4 révélant des attributions d’actions ordinaires de routine à la directrice Elizabeth M. Anderson le 26 juin 2025.

  • Unités d’actions restreintes (RSU) : Anderson a reçu 3 142 actions ordinaires gratuitement, portant sa propriété directe à 23 215 actions (incluant les nouvelles RSU).
  • Attribution d’options d’achat d’actions : Elle a reçu une option sur 11 574 actions avec un prix d’exercice de 37,48 $, expirant le 26 juin 2035. L’option devient entièrement acquise au premier anniversaire de l’attribution ou juste avant la prochaine assemblée annuelle, à condition qu’elle reste prestataire de services.
  • Participations indirectes : Anderson détient également 26 990 actions via le David W. Anderson 1996 Irrevocable Trust.
  • Aucune cession : Le dépôt ne rapporte aucune vente d’actions RVMD.

Ces transactions représentent une rémunération standard pour les administrateurs et ont un impact négligeable sur le nombre total d’actions ou la structure de gouvernance de l’entreprise. Aucun indicateur de performance, développement stratégique ou autre événement important n’a été divulgué dans ce dépôt.

Revolution Medicines, Inc. (RVMD) reichte am 26. Juni 2025 ein Formular 4 ein, das routinemäßige Aktienzuteilungen an die Direktorin Elizabeth M. Anderson offenlegt.

  • Restricted Stock Units (RSUs): Anderson erhielt 3.142 Stammaktien kostenlos, wodurch ihr direkter Anteil auf 23.215 Aktien anstieg (einschließlich der neuen RSUs).
  • Aktienoptionszuteilung: Ihr wurde eine Option auf 11.574 Aktien mit einem Ausübungspreis von 37,48 $ gewährt, die am 26. Juni 2035 verfällt. Die Option wird vollständig am früheren Zeitpunkt des ersten Jahrestages der Gewährung oder unmittelbar vor der nächsten Hauptversammlung fällig, vorausgesetzt, sie bleibt weiterhin Dienstleisterin.
  • Indirekte Beteiligungen: Anderson meldet außerdem 26.990 Aktien, die über den David W. Anderson 1996 Irrevocable Trust gehalten werden.
  • Keine Veräußerungen: Die Einreichung verzeichnet keine Verkäufe von RVMD-Aktien.

Die Transaktionen stellen eine übliche Vergütung für Direktoren dar und haben einen unerheblichen Einfluss auf die Gesamtzahl der Aktien oder die Governance-Struktur des Unternehmens. Es wurden keine Leistungskennzahlen, strategischen Entwicklungen oder sonstige wesentliche Ereignisse in dieser Einreichung offengelegt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GILMORE GEOFFREY G

(Last) (First) (Middle)
100 OLD WILSON BRIDGE ROAD

(Street)
COLUMBUS OH 43085

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Worthington Steel, Inc. [ WS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 06/27/2025 A(1) 46,465 A $0 303,331 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. An award of restricted stock was granted pursuant to the Worthington Steel Inc. 2023 Long-Term Incentive Plan. The restricted stock will vest on the third anniversary of the grant date (6/27/2028).
/s/ Joseph Y. Heuer, as attorney-in-fact for Geoffrey G. Gilmore 06/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many RVMD RSUs were granted to Director Elizabeth M. Anderson?

3,142 restricted stock units were awarded on 26 June 2025.

What is the size and price of the new RVMD stock option grant?

An option covering 11,574 shares was granted with a $37.48 exercise price.

Did the filing report any sale of Revolution Medicines shares?

No. The Form 4 shows only acquisitions; no dispositions were reported.

What is Elizabeth M. Anderson’s total direct RVMD share ownership after the transactions?

She holds 23,215 shares directly, which include the newly granted RSUs.

When will the newly granted RVMD options fully vest?

They vest on the earlier of 26 June 2026 or immediately before the next annual meeting, contingent on continued service.
Worthington Steel

NYSE:WS

WS Rankings

WS Latest News

WS Latest SEC Filings

WS Stock Data

1.27B
31.28M
36.05%
50.24%
2.3%
Steel
Steel Works, Blast Furnaces & Rolling & Finishing Mills
Link
United States
COLUMBUS